{"changeSha256":"235d305645f8e2e9c72a8af327f2dfc57903a6a9fe3403bd435e24105684d0f6","changedAt":"2026-11-16","changedFields":[{"after":"Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.","before":"FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.","field":"Evidence note"},{"after":"dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026, fda-lantus-label-2023","before":"dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026","field":"Cited source records"},{"after":"name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-lantus-label-2023, fda-langlara-approval-2026","before":"name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-langlara-approval-2026","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/insulin-glargine-aldy/versions/4/","version":4},"id":"profile:insulin-glargine-aldy:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.","peptideSlugs":["insulin-glargine-aldy"],"previousChangeEvent":{"path":"/corrections/v1/profiles/insulin-glargine-aldy/v3.json","sha256":"5e75c53fae432eefb3d85670a009efc39d92d28e13431a93bd40b035403affbf"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/insulin-glargine-aldy/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=5328761e-59d3-ca7a-e063-6394a90ae810&version=5","verifiedAt":"2026-07-22"},{"id":"fda-lantus-label-2023","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Lantus (insulin glargine) prescribing information, application 021081 supplements S-078 and S-079, revised June 2023","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021081s078s079lbl.pdf","verifiedAt":"2026-11-16"},{"id":"fda-langlara-approval-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026","url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761412Orig1s000ltr.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"insulin-glargine-aldy","type":"profile"}}
